Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: NGS of gene using SpRY variants in rice-2

PROVIDER: PRJNA674974 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12998600_1.fastq.gz	Fastqsanger.gz
	SRR12998600_2.fastq.gz	Fastqsanger.gz
	SRR12998601_1.fastq.gz	Fastqsanger.gz
	SRR12998601_2.fastq.gz	Fastqsanger.gz
	SRR12998602_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

Project description:NGS of gene using SpRY variants in rice-1

| PRJNA674916 | ENA

Project description:NGS of gene using spCas9 variants in rice-3

| PRJNA678612 | ENA

Project description:NGS of gene using spCas9-SpG variants in rice

| PRJNA675713 | ENA

Project description:NGS of gene using spCas9 variants in rice-4

| PRJNA679425 | ENA

Project description:NGS of gene using spCas9 variants in rice-5

| PRJNA679420 | ENA

Project description:NGS of gene using spCas9 variants in rice-2

| PRJNA676008 | ENA

Project description:NGS of gene using spCas9 variants in rice-1

| PRJNA674028 | ENA

Project description:NGS of gene using spCas9 variants (spCas9-NG) in rice

| PRJNA679144 | ENA

Project description:NGS of gene using FrCas9 in rice

| PRJNA1025872 | ENA

Base editing effectively prevents the early-onset hypertrophic cardiomyopathy in Mybpc3 mutant mice

Project description:Pathogenic variants in MYBPC3 (myosin-binding protein C3) are the leading cause of genetic hypertrophic cardiomyopathy (HCM). Currently, there is no specific and effective treatment for this disease. Base editing is an emerging modality for treating monogenic diseases; however, its effect on MYBPC3 cardiomyopathy remains unexplored. Mybpc3-R946X/R946X mice developed early-onset left ventricular hypertrophy, systolic dysfunction, ventricular dilatation, and arrythmias. SpRY-ABEmax inefficiently corrected the Mybpc3-R946X mutation. In contrast, SpRY-ABE8e increased the efficiency by 3.6-fold and retained low level off-target editing. In vivo administration of SpRY-ABE8e efficiently corrected Mybpc3-R946X mutation in cardiomyocytes and prevented heart function decline, hypertrophic cardiomyopathy, and ventricular dysfunction. The therapeutic efficacy of SpRY-ABE8e-mediated gene correction surmounted AAV-mediated Mybpc3 gene replacement.Our study unveiled the immense potential of base editing to treat fatal inherited cardiomyopathies and opened a new avenue for the therapeutic managements of inherited cardiac diseases.

2024-04-04 | GSE239872 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data